Johns Hopkins Psychiatry Guide

Alzheimer Disease

Matthew E. Peters, M.D., Constantine G. Lyketsos, M.D.
Alzheimer Disease is a topic covered in the Johns Hopkins Psychiatry Guide.

To view the entire topic, please or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

-- The first section of this topic is shown below --

DEFINITION

  • Alzheimer disease (AD) is a neurodegenerative disease and the most common cause of dementia.
    • AD is thought to account for at least 50% of dementia cases.[1]
    • Dementia is a syndrome characterized by global cognitive decline that significantly affects daily functioning in the absence of delirium.
  • There is growing recognition of individuals with cognitive impairment at a severity level insufficient for a diagnosis of dementia. Two terms have been used to describe these individuals:
    • Cognitive impairment, no dementia (CIND)
    • Mild cognitive impairment (MCI)
  • Cortical atrophy, amyloid-predominant neuritic plaques, tau-predominant neurofibrillary tangles, and neuronal death are hallmarks of the pathological diagnosis of AD confirmed via postmortem histopathological examination.[2]
  • Cascade view of etiopathogenesis of AD[3]:
    • Genetic and environmental risk factors interact to increase the production or to decrease the clearance of a toxic form of a peptide (amyloid beta (abeta) 1-42) derived from turnover of the amyloid precursor protein (APP), a transmembrane protein present on neurons.
    • If APP is processed through cleavage by β-secretase preferentially over α-secretase, this leads to the formation of abeta 1-42 that is prone to dimerization, oligomerization, and deposition in the extracellular space.
    • The deposited abeta 1-42 accumulates close to the synaptic cleft and is thought to lead over time to synaptic disconnection, the loss of neurotransmitter systems, and the emergence of symptoms.
  • Cognitive impairment due to AD is classified under the neurocognitive disorders (NCDs) section of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).[2]

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: March 1, 2017